Multivalent Peptide-Nanoparticle Conjugates for Influenza-Virus Inhibition

Area of Science:

• Nanotechnology
• Virology
• Biomaterials

Background:

• Influenza A virus poses a significant global health threat.
• Current antiviral strategies face challenges like drug resistance.
• Inhibiting virus-host cell binding is a promising therapeutic approach.

Purpose of the Study:

• To develop a novel, non-carbohydrate-based multivalent inhibitor for influenza A virus.
• To investigate the efficacy of peptide-polymer nanoparticles in preventing viral infection.
• To optimize nanoparticle design for enhanced antiviral activity.

Main Methods:

• Generation of multivalent peptide-polymer nanoparticles using dendritic polyglycerol scaffolds.
• Characterization of nanoparticle binding affinity to influenza A virus hemagglutinin.
• In vitro and in vivo evaluation of antiviral efficacy against influenza A virus infection.

Main Results:

• Peptide-polymer nanoparticles demonstrated nanomolar affinity for the influenza A virus.
• Increasing polymer scaffold size and adjusting peptide density significantly reduced viral infection in vitro.
• The developed peptide-polymer conjugate showed efficacy in an in vivo infection model.

Conclusions:

• This study introduces the first non-carbohydrate, covalently linked multivalent virus inhibitor in the nano- to picomolar range.
• The findings highlight the potential of peptide-polymer nanoparticles as a new class of antiviral agents.
• Optimized nanoparticle design, with low peptide-ligand density on larger dendritic scaffolds, is crucial for potent antiviral activity.